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News
Iowa
Board of Pharmacy
Board Member Reappointed
Congratulations to pharmacist Edward McKenna of Storm 
Lake, IA, on his reappointment to the Iowa Board of Pharmacy 
by Governor Terry Branstad. Ed’s new term began on May 1, 
2015, and will end on April 30, 2018.
New Board Member Appointed
Congratulations to pharmacist Jason Hansel of Bettendorf, 
IA. Jason has been appointed to a three-year term on the 
Board by Governor Branstad effective May 1, 2015. Jason is 
a district pharmacy supervisor for Walgreens and is a doctor 
of pharmacy graduate of the University of Iowa College of 
Pharmacy. The Board welcomes Jason and looks forward to 
working with him.
Board Retirements
Pharmacist Susan Frey of Villisca, IA, retired from the 
Board on April 30, 2015. Susan served nine years on the Board, 
beginning on May 1, 2006. While on the Board, Susan also 
served on the Board’s Rules Committee, various task force 
and advisory groups, and as chairperson of the Board.
Executive Director Lloyd K. Jessen retired from the Board 
on March 27, 2015. Lloyd served as the Board’s director since 
January 1990. Prior to serving as director, he was the Board’s 
chief investigator from 1987 to 1990. Lloyd was a member of 
the National Association of Boards of Pharmacy® (NABP®) 
Executive Committee for seven years, from 2006 to 2013.
The Board extends its sincere thanks to Susan and Lloyd for 
their many contributions and their dedicated public service.
Summary of Board Activities
The Board currently oversees the activities of approximately 
35,500 licensees and registrants, including pharmacies, drug 
wholesalers, pharmacists, pharmacist interns, pharmacy 
technicians, pharmacy support persons, precursor vendors and 
recipients, Internet pharmacy sites, and controlled substance 
(CS) registrants. The Board conducts routine inspections of 
pharmacies and drug wholesalers and investigates complaints 
relating to all licensees and registrants. In addition to its licens-
ing and registration programs, the Board has maintained and 
operated the Iowa Prescription Monitoring Program (PMP) 
since its implementation in 2009.
The Board is entirely self-supported through the ongoing 
collection and retention of licensing and registration fees. 
The Board receives no money from the state’s General Fund, 
pursuant to Iowa Code §147.82. The Iowa PMP is funded 
exclusively through the use of fees collected by the Board, 
without any additional funding and without any additional 
costs to pharmacists and prescribers. Every fiscal year since 
the fiscal year beginning July 1, 2007, actual Board revenues 
have exceeded anticipated income, while Board expenditures 
have been less than projected and far below revenues. The 
Board reviews all fees and expenditures at least annually 
and adjusts fees accordingly. The Board reduced all fees by a 
minimum of 10% effective January 16, 2013. This decrease in 
fees provided a direct economic benefit to all Board licensees 
and registrants. No fees have been increased since the fee 
reduction was implemented in 2013.
Since 2010, the Board has experienced a significant increase 
in its workload. There has been a continual rise in the number 
of Board disciplinary cases each decade. The 1980s saw an 
average of 11 cases per year; the 1990s saw an average of 28 
cases per year; and the 2000s saw an average of 31 cases per 
year. The most recent five-year period (2010 through 2014) 
shows a dramatic increase in disciplinary actions, with the 
Board taking action in an average of 74 cases per year. A 
record number of 109 cases came before the Board for resolu-
tion in 2013.
In 2012-2013, the Board oversaw the inspection of 538 
nonresident (out-of-state) pharmacies licensed to do business 
in Iowa. This special project was undertaken in response to 
the pharmacy compounding tragedy in Massachusetts that 
killed 64 people and sickened hundreds of others across the 
country with fungal meningitis in the fall of 2012.
In 2013-2014, the Board issued 515 official documents as 
follows: 135 Board orders or settlement agreements; 112 state-
ments of charges; 135 letters of education; 93 administrative 
warnings; 16 show cause orders relating to CS registrations; 
11 confidential orders for evaluation; 10 combined charges and 
settlement agreements; and three emergency orders.
In addition to its regular duties, the Board sponsored and 
managed the following special advisory committees, task 
forces, and other meetings between 2012 and 2015: the Iowa 
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a) Use a weekly dosage regimen default for oral  
methotrexate. If overridden to daily, require a hard stop 
verification of an appropriate oncologic indication.
b) Provide patient education by a pharmacist for all weekly 
oral methotrexate discharge orders.
Question: Does the best practice of a weekly frequency default 
for oral methotrexate apply to a specialty cancer hospital?
Answer: The intent of this best practice is to reduce errors when 
methotrexate is prescribed as a weekly regimen for non-oncologic 
or oncologic indications. Even when used for oncologic purposes, 
oral methotrexate is sometimes prescribed as a weekly regimen, 
not daily. Thus, this best practice applies to all patient care settings, 
including specialty cancer hospitals.
Teaching Points (Both Verbal and Written)
 ♦ Explain the weekly dosing schedule.
 ♦ Explain that taking extra doses is dangerous.
 ♦ Have the patient repeat back the instructions.
 ♦ Provide the patient with the free ISMP high-alert medication 
consumer leaflet on methotrexate (found at www.ismp.org/
AHRQ/default.asp).
To read all of the best practices, visit www.ismp.org/Tools/Best 
Practices/default.asp.
ACPE Releases Updated Definition of CPE and 
Guidance on CPD
The Accreditation Council for Pharmacy Education (ACPE) 
has released two documents that provide guidance and support for 
continuing pharmacy education (CPE) and continuing professional 
development (CPD). The two documents, approved by the ACPE 
board of directors, are described below.
 ♦ The revised Definition of Continuing Education for the Profes-
sion of Pharmacy defines the quality of CPE required by ACPE 
and the competencies required for CPE activity content. The 
Definition document will assist providers of CPE in planning 
activities that will be applicable to the professional development 
of pharmacists and certified pharmacy technicians.
 ♦ The Guidance on Continuing Professional Development (CPD) 
for the Profession of Pharmacy incorporates feedback from a 
broad survey of the pharmacy profession that was conducted 
in July 2014. The Guidance document provides details on the 
learning activities that may contribute to the professional devel-
opment of both pharmacists and pharmacy technicians beyond 
CPE, and also “provides a process for pharmacists and pharmacy 
technicians to meet and maintain defined competencies in areas 
relevant to their respective professional responsibilities.”
Additional information, including links to the documents, is avail-
able in a press release on the ACPE website at www.acpe-accredit 
.org/pdf/ACPEAdvancesCPE-CPDforPharmacists.pdf.
Hospira Issues Recall for Multiple Lots of 
Ketorolac Tromethamine Injection Due to 
Potential Contamination
Hospira, Inc, of Lake Forest, IL, has issued a voluntary recall 
of ketorolac tromethamine injection, USP in the United States and 
Singapore due to potential particulate matter. The presence of par-
ticulate was confirmed through a customer report of visible floating 
particulate that was identified as calcium-ketorolac crystals. If in-
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FDA’s New Database Simplifies Searching for 
Guidance Documents
Food and Drug Administration (FDA) has released a new database 
that houses most FDA guidance documents for regulatory profession-
als. The guidance documents for nearly all FDA-regulated professions 
and industries are available in a searchable database that allows users 
to enter keywords that update automatically as they are typed. Search 
results may also be narrowed by product, date, document type, and 
other terms. The database also indicates whether there is an open 
comment period and the deadline for submitting comments. 
The database can be accessed at www.fda.gov/Regulatory 
Information/Guidances/default.htm.
2014-2015 Targeted Medication Safety Best 
Practices for Hospitals
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). ISMP is 
an independent nonprofit agency and federally 
certified patient safety organization that analyzes medication errors, 
near misses, and potentially hazardous conditions as reported by 
pharmacists and other practitioners. ISMP then makes appropriate 
contacts with companies and regulators, gathers expert opinion 
about prevention measures, and publishes its recommendations. To 
read about the risk reduction strategies that you can put into practice 
today, subscribe to ISMP Medication Safety Alert!® Community/
Ambulatory Care Edition by visiting www.ismp.org. ISMP provides 
legal protection and confidentiality for submitted patient safety data 
and error reports. Help others by reporting actual and potential 
medication errors to the ISMP National Medication Errors Reporting 
Program Report online at www.ismp.org. Email: ismpinfo@ismp.org.
The purpose of the Targeted Medication Safety Best Practices 
(TMSBP) for Hospitals is to identify, inspire, and mobilize wide-
spread, national adoption of consensus-based best practices on spe-
cific medication safety issues that continue to cause fatal and harmful 
errors in patients despite repeated warnings in ISMP publications. 
These best practices are realistic practices, already adopted by many 
organizations, upon which hospitals can focus their medication safety 
efforts. The best practices are applicable to all types of hospitals in-
cluding, but not limited to, critical access hospitals, cancer hospitals, 
and children’s hospitals. They may also be applicable to other health 
care settings, as well as non-inpatient areas of hospitals and hospital 
systems. These best practices have been reviewed by an external 
expert advisory panel and approved by the ISMP Board of Trustees. 
Related issues of the ISMP Medication Safety Alert! are referenced 
after each best practice.
Recurrent Issue of Serious Harm
Oral methotrexate for non-oncological indications administered 
daily instead of weekly or twice weekly is a recurrent issue and one 
of the six TMSBPs.
ISMP has published this error in seven ISMP Medication Safety 
Alert! issues from 1996 to 2013. Although dosed daily for oncology 
purposes, it is used weekly or twice weekly to treat a variety of 
autoimmune diseases (eg, psoriasis, severe rheumatoid arthritis). 
Error reports point to inadvertent ordering and/or entering as daily 
instead of weekly or twice weekly, and lack of patient education/
understanding of medication dosing schedule. To minimize the risk 
of error, Best Practice 2 calls for hospitals to:
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jected, medications contaminated with particulate matter may cause 
localized inflammation, allergic reaction, granuloma formation, or 
microembolic effects. Multiple lots are impacted by this recall and 
are listed in a press release posted to the FDA website at www.fda 
.gov/Safety/Recalls/ucm433857.htm. The lots were distributed from 
February 2013 to December 2014 in the US. To date, there have been 
no cases of adverse events associated with this medication. Adverse 
reactions may be reported to FDA’s MedWatch Safety Information 
and Adverse Event Reporting Program.
FDA Warns of Counterfeit Cialis Tablets Entering 
the US
Potentially dangerous, counterfeit versions of Cialis® 20 mg tablets 
were intercepted in the mail before reaching a US consumer, warns 
FDA. Laboratory analysis of the counterfeit product showed that it 
contained multiple active ingredients that could lead to adverse effects 
or harm if used, indicates an FDA Drug Safety Announcement. The 
agency reminds US consumers to only buy prescription medications 
from state-licensed pharmacies located in the US. FDA notes that it 
cannot confirm that the manufacturing, quality, storage, and handling 
of products ordered from unlicensed websites follow US standards 
because the products are from an unknown source.
To help consumers identify these counterfeit medications, FDA 
provides guidelines in the safety announcement. For example, these 
counterfeits list “AUSTR81137” on the front of the bottle and lack a 
National Drug Code number. Other possible identifiers include mis-
spellings and unusual colors on the label, and a manufacturer listed as 
“112 Wharf Road, WEST RYDE, NSW 2114” on the side of the bottle.
To date, FDA is not aware of any adverse events associated with 
these counterfeit medications; however, consumers are encouraged 
to talk to a health care provider about their condition and options for 
treatment if a counterfeit product was received.
The National Association of Boards of Pharmacy® (NABP®) has 
reviewed more than 10,900 websites selling prescription drugs to 
patients in the US and found that nearly 97% are operating out of 
compliance with pharmacy laws and practice standards established 
to protect the public health. To help consumers in the US find the 
safest sources for purchasing medications online, NABP developed 
the Verified Internet Pharmacy Practice Sites® (VIPPS®) program. 
NABP encourages consumers to look for the VIPPS Seal and to 
check NABP’s list of accredited sites on the AWARXE® Prescription 
Drug Safety Program website. In addition, consumers may soon 
watch for pharmacy sites using the newly launched .pharmacy Top-
Level Domain; sites in the domain (with a website address ending 
in .pharmacy) will be reviewed by NABP and approved only if they 
are legitimate online pharmacies or pharmacy resources adhering to 
applicable pharmacy laws and best practices.
Additional details on the counterfeit Cialis are available in a Drug 
Safety Announcement posted to the FDA website at www.fda.gov/
Drugs/DrugSafety/ucm431071.htm. More information on VIPPS 
and other NABP programs is available in the Programs section of 
the NABP website, www.nabp.net.
New FDA Drug Info Rounds Training Videos 
Review Drug Disposal and REMS
FDA Drug Info Rounds, a series of online videos, provides impor-
tant and timely drug information to practicing clinical and community 
pharmacists so they can help patients make better decisions. The latest 
Drug Info Rounds videos are as follows.
 ♦ In “Disposal of Unused Medicines,” pharmacists discuss how 
consumers can safely dispose of expired or unused medications 
to prevent abuse or misuse and accidental poisoning.
 ♦ In “REMS,” pharmacists discuss the many components of Risk 
Evaluation and Mitigation Strategies (REMS) and how they can 
help manage a drug product with known or potential serious risks. 
Drug Info Rounds is developed with contributions from pharma-
cists in FDA’s Center for Drug Evaluation and Research, Office of 
Communications, Division of Drug Information. These videos and 
previous Drug Info Rounds resources are available on the FDA web-
site at www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/
ucm211957.htm.
FDA Issues New Drug Labeling Rules to Benefit 
Pregnant, Breastfeeding Women
FDA announced new prescription drug labeling requirements that 
will clarify how medications might affect women who are pregnant or 
breastfeeding and men and women of reproductive potential. The final 
“Content and Format of Labeling for Human Prescription Drug and 
Biological Products; Requirements for Pregnancy and Lactation Label-
ing Rule” removes the previously used pregnancy letter categories – A, 
B, C, D, and X – and places information into three main categories:
 ♦ Pregnancy: Labor and delivery guidelines now fall under this 
category, which also now includes information for pregnancy ex-
posure registries. Such registries track data on the effects of certain 
approved medications on pregnant and breastfeeding women.
 ♦ Lactation: Previously labeled “Nursing Mothers,” this category 
provides information such as how much drug is secreted through 
breast milk and the potential effects on a breastfed infant.
 ♦ Females and Males of Reproductive Potential: This is a new 
category that includes information on how a certain medication 
might affect pregnancy testing, contraception, and infertility.
The new labeling changes go into effect on June 30, 2015. Over-
the-counter medication labels will not be affected. The new rules 
are available for download through the Federal Register at https://
s3.amazonaws.com/public-inspection.federalregister.gov/2014-28241 
.pdf.
FDA Approves Zohydro ER With Abuse-
Deterrent Properties
In February 2015, FDA approved a new formulation of Zohydro® 
ER with abuse-deterrent properties. The new formulation uses a tech-
nology that allows the drug to maintain its release properties when used 
as intended, according to a press release from Zogenix. The abuse-
deterrent system, known as BeadTek, incorporates “pharmaceutical 
excipients” that create a viscous gel when the medication is crushed and 
dissolved in a liquid or solvent, thus making the product more difficult 
to abuse through methods that involve crushing, breaking, or dissolving 
the drug. In early 2014, Zohydro ER became the first extended-release, 
single-ingredient hydrocodone product to receive approval for use in 
the US. Approval of the drug came under criticism, with some orga-
nizations arguing that the potential for addiction, abuse, and misuse 
could outweigh therapeutic benefits, in part because the drug lacked 
abuse-deterrent properties. Zogenix indicates that transition to the new 
abuse-deterrent formulation will take place in second quarter 2015.
Additional information on the new formulation is provided in a press 
release available on the Zogenix website at http://ir.zogenix.com/phoenix 
.zhtml?c=220862&p=irol-newsArticle&cat=news&id=2012326.
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Pharmacy Workplace and Patient Safety Task Force; the Iowa 
Telepharmacy Advisory Committee; the Iowa Pharmacy 
Compounding Task Force; the Iowa Pharmacist-In-Charge/
Pharmacy Owner Task Force; and the Iowa PMP Conference.
Since 1990, the Board has collected $777,702 in fines and 
civil penalties from licensees and registrants as part of the 
Board’s formal disciplinary process. This money goes to the 
state’s General Fund for the economic benefit of all Iowans. It 
is not used to support the Board’s mission or programs. As a 
result, the Board generates revenue for the state of Iowa while 
protecting the health and safety of Iowans by effectively and 
efficiently using its resources to regulate the practice of phar-
macy and the distribution of prescription drugs and devices.
The following table is a summary of disciplinary actions and 
civil penalties imposed by the Board, by decade, since 1980.
1980-
1989
1990-
1999
2000-
2009
2010-
2014  
(Five 
Years)
Total cases 
with disciplin-
ary action
116 285 315 370
Total cases  
involving civil 
penalty
28 83 72 188
Percentage  
of cases 
involving civil 
penalty
24 29 23 51
Total civil  
penalties $26,250 $262,502 $154,200 $334,750
Annual aver-
age penalties $2,625 $26,250 $15,420 $66,950
Average civil 
penalty per 
case
$938 $3,163 $2,142 $1,781
The mission of the Board is to promote, preserve, and 
protect the public health, safety, and welfare though the effec-
tive regulation of the practice of pharmacy and the licensing 
of pharmacies, pharmacists, and others engaged in the sale, 
delivery, or distribution of prescription drugs and devices or 
other classes of drugs or devices which may be authorized, 
pursuant to Iowa Code §155A.2.
The Board’s vision is to lead by promoting the provision 
of safe and effective pharmaceutical care to all Iowans. The 
Board achieves this by maintaining and enforcing minimum 
standards of practice, educating licensees and registrants, 
sponsoring pharmacy outreach programs, conducting pilot 
projects, building creative health care alliances, encouraging 
pharmacist empowerment and innovative pharmacy practice, 
supporting collaborative practice among pharmacists and 
other health care providers, and reducing the incidence of 
prescription drug abuse in Iowa.
The Board received the 2010 NABP Fred T. Mahaffey 
Award during the NABP 106th Annual Meeting for exceptional 
contributions to the protection of the public health and welfare 
and furthering the mission of NABP.
Board Website
Please visit the Board’s website at www.state.ia.us/ibpe for 
more information.
Follow the Board on Facebook and Twitter
Continued from page 1
Facebook “Iowa Board of Pharmacy”
www.facebook.com/pages/Iowa-Board-of-
Pharmacy/223126781053672
Twitter “IABoardPharmacy”
http://twitter.com/#!/IABoardPharmacy
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